Novo Nordisk’s Wegovy approved in China for MASH
Novo Nordisk said Wegovy was approved in China as the first and only GLP-1 receptor agonist for the treatment of MASH.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.